Test Code FIBRO FibroTest-ActiTest, Serum
Reporting Name
FibroTest-ActiTest, SUseful For
Evaluating hepatic fibrosis in chronic hepatitis C patients
Diagnosing fibrosis in carriers of chronic hepatitis B virus
Evaluating hepatic fibrosis in co-infected HIV carriers
Providing access to new-generation non-interferon treatment for hepatitis
Evaluating fibrosis in patients suffering from metabolic conditions (nonalcoholic fatty liver disease) and patients who consume excess alcohol
Performing Laboratory

Specimen Type
SerumShipping Instructions
Necessary Information
Age and sex are required.
Specimen Required
Supplies: Amber Frosted Tube, 5 mL (T192)
Collection Container/Tube:
Preferred: Serum gel
Acceptable: Red top
Submission Container/Tube: Amber vial
Specimen Volume: 3 mL
Collection Instructions:
1. Centrifuge and aliquot serum within 2 hours of collection.
2. Centrifuged serum must be light protected within 4 hours of collection. It is acceptable to draw the blood and then protect it from light after centrifugation as long as it is within 4 hours of collection.
Specimen Minimum Volume
1.5 mL
Testing Algorithm
This test is a patented test algorithm developed by BioPredictive. FibroTest combines 5 standard biomarkers (gamma-glutamyltransferase, total bilirubin, alpha-2-macroglobulin, apolipoprotein A1, and haptoglobin). The ActiTest adds a marker for inflammatory activity (alanine aminotransferase: ALT). These markers are weighted depending on the patient's age and gender.
Testing is compliant with BioPredictive's technical recommendations and approvals.
Specimen Stability Information
Specimen Type | Temperature | Time | Special Container |
---|---|---|---|
Serum | Refrigerated (preferred) | 7 days | LIGHT PROTECTED |
Frozen | 14 days | LIGHT PROTECTED | |
Ambient | 24 hours | LIGHT PROTECTED |
Reference Values
FibroTest-ActiTest, Interpretation
FibroTest Score |
Stage |
Interpretation |
0.00-0.21* |
F0 |
No fibrosis |
0.21-0.27* |
F0-F1 |
No fibrosis |
0.27-0.31* |
F1 |
Minimal fibrosis |
0.31-0.48* |
F1-F2 |
Minimal fibrosis |
0.48-0.58* |
F2 |
Moderate fibrosis |
0.58-0.72* |
F3 |
Advanced fibrosis |
0.72-0.74* |
F3-F4 |
Advanced fibrosis |
0.74-1.00 |
F4 |
Severe fibrosis (Cirrhosis) |
*Boundary values can apply to 2 stages based on rounding. For example, a FibroTest score of 0.305 will round up to 0.31 and be staged F1. A FibroTest score of 0.314 will round down to 0.31 and be staged F1-F2.
ActiTest Score |
Grade |
Interpretation |
0.00-0.17* |
A0 |
No activity |
0.17-0.29* |
A0-A1 |
No activity |
0.29-0.36* |
A1 |
Minimal activity |
0.36-0.52* |
A1-A2 |
Minimal activity |
0.52-0.60* |
A2 |
Significant activity |
0.60-0.62* |
A2-A3 |
Significant activity |
0.62-0.100 |
A3 |
Severe activity |
*Boundary values can apply to 2 grades based on rounding. For example, an ActiTest score of 0.285 will round up to 0.29 and be graded A0-A1. An ActiTest score of 0.294 will round down to 0.29 be graded A1.
ALPHA-2-MACROGLOBULIN
≤18 years: 178-495 mg/dL
>18 years: 100-280 mg/dL
ALANINEAMINOTRANSFERASE (ALT)
Males
<12 months: No established reference values
≥1 year: 7-55 U/L
Females
<12 months: No established reference values
≥1 year: 7-45 U/L
APOLIPOPROTEIN A1
Males
<24 months: No established reference values
2-17 years
Low: <115 mg/dL
Borderline low: 115-120 mg/dL
Acceptable: >120 mg/dL
≥18 years: ≥120 mg/dL
Females
<24 months: No established reference values
2-17 years
Low: <115 mg/dL
Borderline low: 115-120 mg/dL
Acceptable: >120 mg/dL
≥18 years: ≥140 mg/dL
GAMMA-GLUTAMYLTRANSFERASE (GGT)
Males
0-11 months: <178 U/L
12 months-6 years: <21 U/L
7-12 years: <24 U/L
13-17 years: <43 U/L
≥18 years: 8-61 U/L
Females
0-11 months: <178 U/L
12 months-6 years: <21 U/L
7-12 years: <24 U/L
13-17 years: <26 U/L
≥18 years: 5-36 U/L
HAPTOGLOBIN
30-200 mg/dL
BILIRUBIN, TOTAL
0-6 days: Refer to www.bilitool.org for information on age-specific (postnatal hour of life) serum bilirubin values.
7-14 days: <15.0 mg/dL
15 days to 17 years: ≤1.0 mg/dL
≥18 years: ≤1.2 mg/dL
Day(s) and Time(s) Performed
HAPTF, A2MF: Monday through Saturday; 3 p.m.
ALTF, GGTF, TBILF: Monday through Sunday; Continuously
APOAF: Monday through Saturday; Continuously
Test Classification
This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.CPT Code Information
81596
LOINC Code Information
Test ID | Test Order Name | Order LOINC Value |
---|---|---|
FIBRO | FibroTest-ActiTest, S | 48796-7 |
Result ID | Test Result Name | Result LOINC Value |
---|---|---|
TBILF | Bilirubin, Total, S | 1975-2 |
ALTF | Alanine Aminotransferase (ALT), S | 1743-4 |
A2MF | Alpha-2-Macroglobulin, S | 1835-8 |
APOAF | Apolipoprotein A1, S | 1869-7 |
GGTF | Gamma Glutamyltransferase (GGT), S | 2324-2 |
HAPTF | Haptoglobin, S | 46127-7 |
SCRF | FibroTest Score | 48795-9 |
STGF | FibroTest Stage | 48794-2 |
INTEF | FibroTest Interpretation | 88447-8 |
SCRA | ActiTest Score | 48792-6 |
STGA | ActiTest Grade | 48793-4 |
INTEA | ActiTest Interpretation | 88448-6 |
CMMF | FibroTest-ActiTest Comment | 48767-8 |
NUM | BioPredictive Serial Number | 74715-4 |
Clinical Reference
1. BioPredictive: Technical Recommendations for FibroTest and FibroMax assays, Bio Predictive. Accessed February 2018. Available at biopredictive.com/products/fibromax/
2. Halfon P, Bourliere M, Deydier R, et al: Independent prospective mulitcenter validation of biochemical markers (FibroTest-ActiTest) for the prediction of liver fibrosis and activity in patients with chronic hepatitis C: the fibropaca study. Am J Gastroenterol. 2006 Mar;101(3):547-555. doi: 10.1111/j.1572-0241.2006.00411.x
3. Houot M, Ngo Y, Munteanu M, Marque S, Poynard T: Systematic review with meta-analysis: direct comparisons of biomarkers for the diagnosis of fibrosis in chronic hepatitis C and B. Aliment Pharmacol Thera. 2016 Jan;43:16-29. doi: 10.1111/apt.13446
4. Anastasiou J, Alisa A, Virtue S, Portmann B, Murray-Lyon I, Williams R: Noninvasive markers of fibrosis and inflammation in clinical practice: prospective comparison with liver biopsy. Eur J Gastroenterol Hepatol. 2010 Apr;22(4):474-480. doi: 10.1097/MEG.0b013e328332dd0a
5. MartÃnez SM, Crespo G, Navasa M, Forns X: Noninvasive assessment of liver fibrosis. Hepatology. 2011 Jan;53(1):325-335. doi: 10.1002/hep.24013
Method Description
FibroTest-ActiTest, Interpretation:
Proprietary algorithm owned by BioPredictive.
Alpha-2-Macroglobulin and Haptoglobin:
In this method, the light scattered onto the antigen-antibody complexes is measured. The intensity of the measured scattered light is proportional to the amount of antigen-antibody complexes in the sample under certain conditions. If the antibody volume is kept constant, the signal behaves proportionally to the antigen volume.
A reference curve is generated by a standard with a known antigen content on which the scattered light signals of the samples can be evaluated and calculated as an antigen concentration. Antigen-antibody complexes are formed when a sample containing antigen and the corresponding antiserum are put into a cuvette. A light beam is generated with a light-emitting diode, which is transmitted through the cuvette. The light is scattered onto the immuno-complexes that are present. Antigen and antibody are mixed in the initial measurement, but no complex is formed yet. An antigen-antibody complex is formed in the final measurement.
The result is calculated by subtracting value of the final measurement from the initial measurement. The distribution of intensity of the scattered light depends on the ratio of the particle size of the antigen-antibody complexes to the radiated wavelength.(Unpublished Mayo method; Instruction manual: Siemens Nephelometer II, Siemens, Inc; Version 2.3. 2008; Addendum to the Instruction Manual 2.3, 08/2017)
Alanine Aminotransferase (ALT):
Alanine a minotransferase (ALT) activity is determined by a kinetic method using a coupled enzyme reaction where the rate of NADH consumption is measured at 340 nm. The NADH decrease is directly proportional to the ALT activity.(Package insert: Roche ALT reagent. Roche Diagnostics; 2018)
Apolipoprotein A1:
Anti-apolipoprotein A-1 antibodies react with the antigen in the sample to form antigen/antibody complexes which, following agglutination, can be measured turbidimetrically.(Package insert: Tina-quant Apolipoprotein A-1. Roche Diagnostics; 2019)
Gamma-Glutamyltransferase (GGT):
This is an enzyme colorimetric method (rate method) where gamma-glutamyltransferase (GGT) transfers the gamma-glutamyl group of the substrate (L-gamma-glutamyl-3-carboxy-4-nitroanilide) to glycylglycine. The amount of 5-amino-2-nitrobenzoate liberated is proportional to the GGT activity and can be determined photometrically.(Package insert: Boehringer Mannheim GGT reagent. Boehringer Mannheim; 2017)
Bilirubin, Total:
Total bilirubin, in the presence of a suitable solubilizing agent, is coupled with 3,5-dichlorophenyl diazonium in a strongly acidic medium. The color intensity of the red azo dye formed is directly proportional to the total bilirubin and can be determined photometrically.(Package insert: Bilirubin Total Gen. 3. Roche Diagnostics; 2019)
Analytic Time
1 dayReject Due To
Gross hemolysis | Reject |
Gross lipemia | Reject |
Gross icterus | Reject |
Patients <2 years of age | Reject |
Method Name
INTF: Algorithm and interpretation provided through BioPredictive.
APOAF: Automated Turbidimetric Immunoassay
A2MF: Nephelometry
HAPTF: Nephelometry
ALTF: Photometric Rate, L-Alanine with Pyridoxal-5-Phosphate
GGTF: Photometric Rate
TBILF: Photometric, Diazonium Salt (DPD)
Forms
If not ordering electronically, complete, print, and send 1 of the following forms with the specimen:
-General Request (T239)
Secondary ID
38292Profile Information
Test ID | Reporting Name | Available Separately | Always Performed |
---|---|---|---|
INTF | FibroTest-ActiTest, Interpretation | No | Yes |
APOAF | Apolipoprotein A1, S | No | Yes |
A2MF | Alpha-2-Macroglobulin, S | Yes, (Order A2M) | Yes |
HAPTF | Haptoglobin, S | Yes, (Order HAPT) | Yes |
ALTF | Alanine Aminotransferase (ALT), S | Yes, (Order ALT) | Yes |
GGTF | Gamma Glutamyltransferase (GGT), S | Yes, (Order GGT) | Yes |
TBILF | Bilirubin, Total, S | Yes, (Order BILIT) | Yes |